To assess the superiority of fesoterodine @ mg vs @ mg for improvement in urgency urinary incontinence ( UUI ) episodes and other diary variables , diary-dry rate ( proportion of patients with > @ UUI episodes on baseline diary and @ UUI episodes on post-baseline diary ) , and improvements in measures of symptom bother , health-related quality of life ( HRQL ) , and other patient-reported outcomes ( PROs ) .